Re RNS.4 Oct 2018 14:30
It's really quite surprising how many people do not read the complete details, here it is, in black and white.
As indicated in the directors' report of our latest annual report, the Board remains committed to maintain the pace of our development and manufacture activities in order to treat first patients in the second half of 2020. This will involve further funding to include - in particular - the cost of software development and the testing assembly centre at STFC, two key activities required for successful commercial deployment. Yesterday's announcement is placing the Company on a stronger foothold to deliver such a strategy.
Finally, work at our Harley Street facility remains on track and we have complete confidence in our ability to deliver on our plan. On behalf of the Board and the rest of the staff, I would like to thank our shareholders for their continued support and I look forward to updating the market with positive news very soon.
Dr. Michael Sinclair
Executive Chairman
28 September 2018